Results from a Phase 3 study of treatment with investigational tolebrutinib show a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing… read more.
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL… read more.
Long-term exposure to high levels of air pollution may harm the brain health of older adults in England, finds a new study led by UCL researchers. The research,… read more.
H. Lundbeck A/S (Lundbeck) announced that recent pipeline data will be presented at the 2025 AAN Annual Meeting in San Diego, U.S. The data includes an oral presentation… read more.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of… read more.
Compared with people with elevated levels of low-density lipoprotein cholesterol (LDL-C), researchers report that people with lower levels of LDL-C have a relatively lower risk of developing dementia…. read more.
Researchers report a significantly increased risk of dementia in patients diagnosed with atrial fibrillation (AF) in midlife, and a significantly increased risk of early-onset dementia (EOD) as well…. read more.
29th EAHP Congress highlights Cigarette smoking is a well-recognised risk factor for stroke and measures to reduce the prevalence of cigarette smoking have been implemented in many countries…. read more.
Neurocrine Biosciences, Inc. presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated with once-daily Ingrezza (valbenazine) capsules…. read more.
Eisai Co., Ltd. announced the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai’s anti-amyloid beta (Aβ) protofibril* antibody for the treatment… read more.
ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s… read more.
Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
